This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Axsome (AXSM) Q2 Earnings Beat, Stock Dips on Pipeline Updates
by Zacks Equity Research
Axsome (AXSM) incurs a narrower-than-expected loss in the second quarter. The company provides updates on its central nervous system candidates.
ADCTPositive Net Change JAZZPositive Net Change IMGNPositive Net Change AXSMPositive Net Change
biotechnology earnings medical
Viatris (VTRS) Q2 Earnings Beat, Generics Business Grows
by Zacks Equity Research
Viatris (VTRS) second-quarter earnings and sales beat estimates. The company reiterates its annual guidance.
DVAXPositive Net Change ALKSNegative Net Change VTRSNegative Net Change
biotechnology pharmaceuticals
Ligand (LGND) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Ligand's (LGND) second-quarter 2023 performance is likely to have been driven by rising royalty revenues on the back of higher growth in sales of drugs developed using its pelican platform.
AMGNPositive Net Change LGNDPositive Net Change KODPositive Net Change
biotechnology earnings medical
Bull of the Day: NVIDIA (NVDA)
by Kevin Cook
Shares have ramped, but analysts still underestimate the King of AI and its new paradigm
NVDAPositive Net Change AMDPositive Net Change MSFTNegative Net Change CDNSNegative Net Change METAPositive Net Change
aerospace artificial-intelligence automation autonomous-vehicles biotechnology cloud-computing genomics semiconductor software
Gilead's (GILD) Q2 Earnings Miss, Revenues Beat on Oncology
by Zacks Equity Research
Gilead's (GILD) Q2 earnings miss on litigation charges while revenues beat on strong oncology and HIV franchise.
GSKPositive Net Change DVAXPositive Net Change ALKSNegative Net Change GILDPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Intellia (NTLA) Misses on Q2 Earnings, Gives Pipeline Update
by Zacks Equity Research
Intellia's (NTLA) second-quarter earnings miss estimates. The company provides an update on its gene-editing pipeline.
REGNPositive Net Change ADCTPositive Net Change IMGNPositive Net Change NTLANegative Net Change
biotechnology earnings medical
Prothena (PRTA) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Prothena (PRTA) reports a wider-than-expected loss in the second quarter. The company makes considerable pipeline progress and updates 2023 bottom-line guidance.
RHHBYPositive Net Change BMYPositive Net Change NVONegative Net Change PRTANegative Net Change
biotechnology earnings medical
Agios (AGIO) Q2 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
Agios (AGIO) reports narrower-than-expected loss in the second quarter of 2023. The revenues are in line with the Zacks Consensus Estimate.
ALNYPositive Net Change ADCTPositive Net Change IMGNPositive Net Change AGIOPositive Net Change
biotechnology earnings medical
Regeneron (REGN) Q2 Earnings & Sales Top, Eylea Sales Decline
by Zacks Equity Research
Regeneron (REGN) beats earnings and sales estimates in second-quarter 2023 fueled by Dupixent. However, sales of the lead drug, Eylea, decline yet again.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs pharmaceuticals
Corcept (CORT) Beats on Q2 Earnings, Ups '23 Sales View
by Zacks Equity Research
Corcept's (CORT) second-quarter earnings and revenues beat estimates. The company gives updates on its pipelines and raises revenue guidance for 2023, reflecting strong performance of Korlym.
MRKNegative Net Change ADCTPositive Net Change IMGNPositive Net Change CORTPositive Net Change
biotechnology earnings medical
Amarin (AMRN) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amarin's (AMRN) second-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.
ADCTPositive Net Change IMGNPositive Net Change AMRNPositive Net Change
biotechnology earnings medical
Repligen (RGEN) Beats on Q2 Earnings, Lowers '23 Guidance
by Zacks Equity Research
Repligen's (RGEN) second-quarter earnings and revenues beat their respective Zacks Consensus Estimate. Chromatography and process analytics businesses are the key growth drivers in the quarter.
ADCTPositive Net Change IMGNPositive Net Change RGENNegative Net Change
biotechnology earnings medical
3 Top Breakout Stocks to Invest in for Excellent Returns
by Tirthankar Chakraborty
First Watch Restaurant Group (FWRG), VersaBank (VBNK), and Amicus Therapeutics (FOLD) have been selected as the breakout stocks for today.
FOLDPositive Net Change VBNKPositive Net Change FWRGPositive Net Change
biotechnology restaurants
Exelixis (EXEL) Q2 Earnings Top, Cabometyx Drives Growth
by Zacks Equity Research
Exelixis (EXEL) beats second-quarter 2023 earnings and sales estimates as Cabometyx drives growth in approved indications.
BMYPositive Net Change TEVAPositive Net Change ALKSNegative Net Change EXELPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Intercept (ICPT) Q2 Earnings Top Estimates, Revenues Up Y/Y
by Zacks Equity Research
Intercept (ICPT) reports a lower net loss and beats on revenues in the second quarter. The company also updates its guidance for its lead drug, Ocaliva.
DVAXPositive Net Change ALKSNegative Net Change ICPTPositive Net Change VKTXPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Esperion (ESPR) Q2 Earnings Top, Stock Up on Strong Revenues
by Zacks Equity Research
Esperion's (ESPR) second-quarter earnings and revenues beat estimates. The stock surged 7.64% on Tuesday.
ADCTPositive Net Change IMGNPositive Net Change ESPRPositive Net Change
biotechnology earnings medical
ImmunoGen (IMGN) Stock Down Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
ImmunoGen's (IMGN) Q2 earnings show an encouraging adoption of the sole-marketed drug Elahere. The company, however, did not issue any product sales guidance for Elahere for 2023.
VRTXNegative Net Change ADCTPositive Net Change IMGNPositive Net Change
biotechnology earnings medical
Incyte (INCY) Beats on Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Incyte (INCY) reports impressive Q2 earnings on strong uptake in Jakafi and Opzelura sales. The company raises the bottom end of full-year guidance, setting a new range of $2.58-$2.63 billion.
NVSPositive Net Change LLYPositive Net Change INCYNegative Net Change REPLPositive Net Change
biotechnology earnings medical
ANI Pharmaceuticals (ANIP) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
ANI Pharmaceuticals' (ANIP) second-quarter 2023 performance is likely to have been driven by rising generic and rare disease product revenues.
MRNANegative Net Change ANIPPositive Net Change ACADPositive Net Change AXSMPositive Net Change
biotechnology earnings medical
Regeneron (REGN) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Investors' focus is likely to be on the performance of lead drugs Eylea and Dupixent when Regeneron (REGN) reports its second-quarter 2023 results.
REGNPositive Net Change SNYPositive Net Change SRPTPositive Net Change ACADPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Gilead (GILD) Gears Up to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its second-quarter 2023 results.
NVONegative Net Change GILDPositive Net Change SRPTPositive Net Change ACADPositive Net Change
biotechnology biotechs earnings pharmaceuticals
ADMA Biologics (ADMA) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
On ADMA Biologics' (ADMA) Q2 earnings call, investors will likely focus on the sales performance of its immune deficiency disorder drugs.
MRNANegative Net Change ADMAPositive Net Change ACADPositive Net Change AXSMPositive Net Change
biotechnology earnings medical
Bristol-Myers (BMY) Q2 Earnings, Sales Miss, '23 View Lowered
by Zacks Equity Research
Bristol-Myers' (BMY) second-quarter 2023 earnings and sales miss estimates due to generic erosion for the oncology drug Revlimid. The company also cuts its forecast for 2023.
NVSPositive Net Change BMYPositive Net Change PFENegative Net Change ALKSNegative Net Change
biotechnology earnings pharmaceuticals
Roche (RHHBY) 1H Revenues, Earnings Down on Lower COVID-19 Test Sales
by Zacks Equity Research
Roche's (RHHBY) performance in the first half of 2023 was ordinary as COVID-19-test sales continue to decline and dent the top line.
REGNPositive Net Change NVSPositive Net Change RHHBYPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Alkermes (ALKS) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Alkermes (ALKS) reports encouraging second-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.
JNJNegative Net Change ALKSNegative Net Change ADCTPositive Net Change ACADPositive Net Change
biotechnology earnings medical